自免龙头亚辉龙全球布局对冲关税风险

Core Viewpoint - The company, Shenzhen Aihuilong Biotechnology Co., Ltd., has a robust and self-controlled core technology, with a balanced global layout and minimal reliance on the U.S. market, which accounts for less than 1% of its business [2][3]. Group 1: Company Overview - Aihuilong has been deeply engaged in the in vitro diagnostic field for nearly 20 years, establishing a complete industrial ecosystem from raw material development to product research, production, and sales [2]. - The company has invested over 800 million yuan in research and development over the past three years, establishing six R&D centers in cities including Shenzhen, Beijing, and Tokyo, with a team of over 700 researchers [2]. - As of December 31, 2024, Aihuilong has applied for 519 patents, with 156 granted, and 60% of the applications being invention patents, achieving a 55% authorization rate for effective invention patents over the past five years [2]. Group 2: Market Performance - In the fourth quarter of 2024, the company's overseas market revenue reached 106 million yuan, a year-on-year increase of 130.55%, demonstrating the effectiveness of its "local innovation + global expansion" strategy [3]. - The company has seen significant revenue growth in regions such as the Commonwealth of Independent States, South Asia, and the Middle East, with operational centers in Saudi Arabia and Egypt already in use [3]. Group 3: Product and Service Offerings - Aihuilong focuses on unmet needs in the global autoimmune diagnostics market, offering specialized product service packages across seven fields, including autoimmune diseases, reproductive health, liver disease, diabetes, and myocardial infarction [4]. - The company aims to gain international recognition through high-quality and cost-effective services, alongside innovative and distinctive products [4].